Möchten Sie immer auf dem neuesten Stand bleiben?

MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal...

Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025

A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studiesComprehensive access to...

Palo Alto, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal...

Palo Alto, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal...

LAKELAND, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Metrc, a leading provider of regulatory track-and-trace systems for highly regulated industries, announced a strategic partnership with BioTrack, a...

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia

London, July 17, 2025 (GLOBE NEWSWIRE) -- The Centre for Information Policy Leadership (CIPL), a global data and privacy think tank founded in 2001 by leading companies and Hunton Andrews Kurth LLP,...

CEO's personal contribution fully funds build-out and first-year operationsDoubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI...

DURHAM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life...